Biopsy Devices Market worth $12.6 billion by 2028

November 23 09:32 2023
Biopsy Devices Market worth $12.6 billion by 2028
prominent players in the biopsy devices market are Becton, Dickinson and Company (U.S.), Devicor Medical Products, Inc., (Leica Biosystems) (Germany), B. Braun Melsungen AG (Germany), Cardinal Health, Inc. (U.S.), and Hologic, Inc. (US).
Biopsy Devices Market in terms of revenue was estimated to be worth $6.6 billion in 2023 and is poised to reach $12.6 billion by 2028, growing at a CAGR of 14.0% from 2023 to 2028 according to a new report by MarketsandMarkets.

Biopsy Devices Market in terms of revenue was estimated to be worth $6.6 billion in 2023 and is poised to reach $12.6 billion by 2028, growing at a CAGR of 14.0% from 2023 to 2028 according to a new report by MarketsandMarkets. The major factors driving the growth of this market include Progress in medical technology has resulted in the creation of increasingly accurate and less invasive biopsy instruments, thereby mitigating patient discomfort and expediting recovery periods.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132886515

Technology segment to register significant growth rate over the forecast period of 2023-2028

Based on product, the global biopsy devices market is segmented into Needle Based Biopsy Instruments, Localization Wire, Procedure Tray, Biopsy Table and other biopsy products. The Needle Based Biopsy Instruments segment is anticipated to register the highest growth rate over the forecast period.

Biopsy segment in application to register significant growth rate over the forecast period of 2023-2028

Based on end user, the global biopsy devices market is segmented into biopsy, bone marrow biopsy, lung, colorectal, kidney, prostate and others. Biopsy devices are medical tools used to extract a sample of tissue from a patient for diagnostic purposes. These devices are utilized by various healthcare professionals and organizations. Other end users may include healthcare professionals such as physicians, surgeons, and medical practitioners who perform biopsies as part of their clinical practice.The  biopsy segment is anticipated to register the highest growth rate over the forecast period.

The hospitals and are centers segment accounted for the largest share of the biopsy devices market, by end user, in 2022

Based on end user, the multimodal market is segmented into hospitals and care centers, diagnostic imaging centres, research and academia and other end users. The hospitals and  care centers segment accounts for the largest share of the market in 2022. As cancer awareness and screening programs expand, more patients are seeking diagnostic services in hospitals and specialized care centers. Secondly, advancements in imaging technologies and screening techniques have led to an increased demand for biopsy procedures in these settings to confirm diagnoses and plan personalized treatment strategies.

The Asia Pacific market to register a significant growth in the market during the forecast period

The Asia Pacific biopsy devices market is estimated to register a significant growth from 2023 to 2028. The increasing patient population, rising geriatric population, rapid economic growth and increasing disposable income are driving the market growth in APAC countries. This region is having a rise in healthcare investment and expenditure, offering significant growth opportunities for the key players.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132886515

Biopsy Devices Market Dynamics:

Drivers:

1.  Rising prevalence of cancer

Restraints:

1.  Risk of infections

Opportunities:

1.  Technological Advancements

Challenge:

1.  Underdeveloped healthcare infrastructure and dearth of resources in developing countries

Key Market Players of Biopsy Devices Industry:

As of 2022, prominent players in the biopsy devices market are Becton, Dickinson and Company (U.S.), Devicor Medical Products, Inc., (Leica Biosystems) (Germany), B. Braun Melsungen AG (Germany), Cardinal Health, Inc. (U.S.), and Hologic, Inc. (US).

Recent Developments:

  • In December 2022, Olympus entered into a definitive agreement, subsequently finalizing the acquisition of all outstanding shares of Odin Medical Ltd., a cloud-AI endoscopy company based in the UK. This acquisition was conducted through Olympus’ UK subsidiary, Keymed (Medical & Industrial Equipment) Ltd.
  • In November 2021, B. Braun and REVA Medical announced the strategic partnership for the distribution of Fantom Encore – a bioresorbable scaffold for coronary interventions, manufactured with REVA’s patented material Tyrocore. B. Braun will start active distribution of the products in Germany and Switzerland in November 2021, with additional countries to follow afterwards.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=132886515

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/biopsy-device-market-132886515.html